| Literature DB >> 26398358 |
Nadège Philippe1, Laure Maigre1, Sébastien Santini2, Elizabeth Pinet1, Jean-Michel Claverie2, Anne-Véronique Davin-Régli1, Jean-Marie Pagès1, Muriel Masi1.
Abstract
Infections caused by multidrug resistant (MDR) bacteria are a major concern worldwide. Changes in membrane permeability, including decreased influx and/or increased efflux of antibiotics, are known as key contributors of bacterial MDR. Therefore, it is of critical importance to understand molecular mechanisms that link membrane permeability to MDR in order to design new antimicrobial strategies. In this work, we describe genotype-phenotype correlations in Enterobacter aerogenes, a clinically problematic and antibiotic resistant bacterium. To do this, series of clinical isolates have been periodically collected from two patients during chemotherapy with imipenem. The isolates exhibited different levels of resistance towards multiple classes of antibiotics, consistently with the presence or the absence of porins and efflux pumps. Transport assays were used to characterize membrane permeability defects. Simultaneous genome-wide analysis allowed the identification of putative mutations responsible for MDR. The genome of the imipenem-susceptible isolate G7 was sequenced to closure and used as a reference for comparative genomics. This approach uncovered several loci that were specifically mutated in MDR isolates and whose products are known to control membrane permeability. These were omp35 and omp36, encoding the two major porins; rob, encoding a global AraC-type transcriptional activator; cpxA, phoQ and pmrB, encoding sensor kinases of the CpxRA, PhoPQ and PmrAB two-component regulatory systems, respectively. This report provides a comprehensive analysis of membrane alterations relative to mutational steps in the evolution of MDR of a recognized nosocomial pathogen.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26398358 PMCID: PMC4580588 DOI: 10.1371/journal.pone.0138828
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Phenotypic characterization of E. aerogenes strains.
| Patient P | Patient G | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nb of days | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 7 | 14 | 21 | 28 | 35 | 42 | 49 | 56 | 63 | 70 | 91 | |||
| Imipenem treatment | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | |||||||
| Cefpirome treatment | + | |||||||||||||||||||||||||||
| Sampling site | T | T | T | T | T | U | V | S | V | V | B | T | ||||||||||||||||
| Chloramphenicol | R | R | R | R | R | R | R | R | R | R | R | R | S | |||||||||||||||
| Fleroxacin | S | R | R | R | R | R | R | R | R | R | R | R | S | |||||||||||||||
| Norfloxacin | S | R | R | R | R | R | R | R | R | R | R | R | S | |||||||||||||||
| Nalidixic acid | S | R | R | R | R | R | R | R | R | R | R | R | S | |||||||||||||||
| Erythromycin | R | R | R | R | R | R | R | R | R | R | R | R | R | |||||||||||||||
| Imipenem | S | R | S | R | R | S | R | S | S | R | R | S | S | |||||||||||||||
| Ertapenem | S | R | S | R | R | S | R | S | S | R | R | S | S | |||||||||||||||
| Cefepime | S | R | S | R | R | R | R | S | S | R | R | S | S | |||||||||||||||
| Ceftazidime | S | R | R | R | R | R | R | R | R | R | R | R | S | |||||||||||||||
| Cefotaxime | S | R | R | R | R | R | R | S | S | R | R | S | S | |||||||||||||||
| Polymyxin B | S | S | S | S | S | S | S | S | S | R | S | S | S | |||||||||||||||
| Tetracycline | S | R | R | R | R | S | R | R | R | R | R | R | S | |||||||||||||||
| Isolate | P1 | P2 | P3 | P4 | P5 | G1 | G2 | G3 | G4 | G5 | G6 | G7 | ATCC15038 | |||||||||||||||
| Porins | + | - | + | - | - | + | - | + | + | - | - | + | + | |||||||||||||||
| Efflux Pump Proteins | + | + | + | + | + | + | + | + | + | + | + | + | + | |||||||||||||||
E. aerogenes isolates were recovered periodically from two patients undergoing chemotherapy with imipenem—P1 to P5 from patient P and G1 to G7 from patient G. ATCC15038 was used as a reference strain. MICs were determined by broth microdilution in MHII broth as described in Materials and Methods. For clarity, strains have been classified as R for resistant and S for susceptible. Detailed MICs are presented in supplementary information (S1 Table). Different classes of antibiotics were tested: phenicols (chloramphenicol), quinolones (nalidixic acid, fleroxacin and norfloxacin), macrolides (erythromycin), carbapenems (imipenem and ertapenem), cephalosporins (cefepime, ceftazidime and cefotaxime), tetracycline and polymyxin B. Gentamicin is often the last option to treat MDR strains. For this reasons, we chose not to include this antibiotic in our assays but we refer to MIC values obtained from the healthcare facilities.
Sampling sites: U, urine; V, vagina; S, Sputum; B, blood; T, trachea.
The presence of porins and efflux pump proteins were determined immunoblots using specific antibodies directed against Escherichia coli OmpF, OmpC, AcrA, AcrB or TolC.
*Mass spectrometry analysis indicated that porin-plus isolates only express Omp36 whereas strain ATCC15038 expresses both Omp36 and Omp35 (S1 Fig and S2 Table).
Fig 1Hoechst 33342 influx into E. aerogenes strains.
Strains were grown in LB broth and cells were harvested at the beginning of the stationary phase. Cells were washed, resuspended in PPB pH 7.0, and the H33342 influx was assayed in the presence of 50 μM CCCP. A. Chemical structure of H33342. B. Kinetics of H33342 influx. AU, arbitrary units. C. Total accumulation in E. aerogenes isolates after normalization to that of strain ATCC15038. All values are means of at least three independent experiments.
Fig 2Fleroxacin accumulation in E. aerogenes strains.
Strains were grown in LB broth and cells were harvested at mid-log phase. Cells were washed and concentrated 10-fold in NaPi pH 7.0 supplemented with Mg2+. Fleroxacin (FLX) was added to the bacterial suspensions in the absence or in the presence of 10 μM CCCP. After a 30 min incubation time, bacterial lysates were prepared as described in Materials and Methods. The concentration of FLX in the lysates was estimated after normalization of the spectra to their corresponding tryptophan emission peak at 356 nm. The antibiotic-free control time-zero was subtracted from the values obtained for each assay. All values are means of at least three independent experiments.
Fig 3Real-time efflux of 1,2'-DNA in E. aerogenes strains.
Strains were grown in LB broth for 24 h at 37°C and cells were harvested by centrifugation. Cells were deenergized by an overnight incubation in Mg-PPB pH 7.0 with 5 μM CCCP and loaded with 1,2’-DNA. Cells were then washed, resuspended in Mg-PPB pH 7.0 and 1,2’-DNA efflux was monitored after rapid reenergization with glucose. RFU, relative fluorescence units. All values are means of at least three independent experiments.
Summary of genome analysis.
| Isolate | P2-P5 | G1 | G2-G6 | |
|---|---|---|---|---|
| Coverage (% to the reference strain after mapping) | Chromosome pGPN1 | 98.2 95.1 | 96.6 95.2 | 99.1 95.3 |
| Reads (∼ % of mapped) | 85 | 92 | 93 | |
| SNPs and InDels | 70–72 | 92 | 7–11 |
Fig 4Genome of E. aerogenes G7.
This figure was generated with GCviewer (http://stothard.afns.ualberta.ca/cgview_server/) and shows the map of the chromosome and plasmid pGPN1 (174 Kbp) of E. aerogenes isolate G7 obtained by de novo sequencing and assembly.
Features of the G7 genome.
CDS, coding sequences; ICE, integrative and conjugative element; IS, insertion sequence. * Data refer to the chromosome only, except when plasmids are indicated.
| E. aerogenes G7 * | |
|---|---|
| Size (bp) | 5,452,368 |
| GC content (%) | 54.92 |
| CDS (n) | 5,267 |
| rRNAs (n) | |
| 16S | 8 |
| 23S | 8 |
| 5S | 9 |
| tRNAs (n) | 87 |
| Plasmids (n) | 2 |
| Prophages (n) | 8 |
| PhageG7.1 | Intact |
| PhageG7.2 | Intact |
| PhageG7.3 | Questionable |
| PhageG7.4 | Intact |
| PhageG7.5 | Incomplete |
| PhageG7.6 | Questionable |
| PhageG7.7 | Intact |
| PhageG7.8 | Questionable |
| ICEs (n) | 1 |
| IS elements (n) | 4 |
| IS5075 | 3 |
| IS1351 | 1 |
Fig 5Model of intra-patient evolution of E. aerogenes during antibiotic treatment.
Plain arrows represent the putative evolution of bacterial subpopulations in patient P (A) and patient G (B). The genomic distance between the first isolates (P1 and G1) and the subsequent strains (P2-P5 and G2-G7) indicates that these have evolved from other ancestors (P0 and G0). Lack of evidence of genotypic reversion (Rev) from resistant to susceptible strains within the G series suggest alternative evolutionary pathways represented by dotted arrows. Clinical timelines are indicated from day (D) 1 to D12 and week (W) 1 to W13 for patient P and patient G, respectively. IMI, imipenem; CEF, cefpirome.